Lesional Antibody Synthesis and Complement Deposition Associate With De Novo Antineuronal Antibody Synthesis After Spinal Cord Injury.
Journal
Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
12
07
2022
accepted:
06
01
2023
medline:
7
4
2023
entrez:
5
4
2023
pubmed:
6
4
2023
Statut:
epublish
Résumé
Spinal cord injury (SCI) disrupts the fine-balanced interaction between the CNS and immune system and can cause maladaptive aberrant immune responses. The study examines emerging autoantibody synthesis after SCI with binding to conformational spinal cord epitopes and surface peptides located on the intact neuronal membrane. This is a prospective longitudinal cohort study conducted in acute care and inpatient rehabilitation centers in conjunction with a neuropathologic case-control study in archival tissue samples ranging from acute injury (baseline) to several months thereafter (follow-up). In the cohort study, serum autoantibody binding was examined in a blinded manner using tissue-based assays (TBAs) and dorsal root ganglia (DRG) neuronal cultures. Groups with traumatic motor complete SCI vs motor incomplete SCI vs isolated vertebral fracture without SCI (controls) were compared. In the neuropathologic study, B cell infiltration and antibody synthesis at the spinal lesion site were examined by comparing SCI with neuropathologically unaltered cord tissue. In addition, the CSF in an individual patient was explored. Emerging autoantibody binding in both TBA and DRG assessments was restricted to an SCI patient subpopulation only (16%, 9/55 sera) while being absent in vertebral fracture controls (0%, 0/19 sera). Autoantibody binding to the spinal cord characteristically detected the substantia gelatinosa, a less-myelinated region of high synaptic density involved in sensory-motor integration and pain processing. Autoantibody binding was most frequent after motor complete SCI (grade American Spinal Injury Association impairment scale A/B, 22%, 8/37 sera) and was associated with neuropathic pain medication. In conjunction, the neuropathologic study demonstrated lesional spinal infiltration of B cells (CD20, CD79a) in 27% (6/22) of patients with SCI, the presence of plasma cells (CD138) in 9% (2/22). IgG and IgM antibody syntheses colocalized to areas of activated complement (C9neo) deposition. Longitudinal CSF analysis of an additional single patient demonstrated de novo (IgM) intrathecal antibody synthesis emerging with late reopening of the blood-spinal cord barrier. This study provides immunologic, neurobiological, and neuropathologic proof-of-principle for an antibody-mediated autoimmunity response emerging approximately 3 weeks after SCI in a patient subpopulation with a high demand of neuropathic pain medication. Emerging autoimmunity directed against specific spinal cord and neuronal epitopes suggests the existence of paratraumatic CNS autoimmune syndromes.
Sections du résumé
BACKGROUND AND OBJECTIVES
Spinal cord injury (SCI) disrupts the fine-balanced interaction between the CNS and immune system and can cause maladaptive aberrant immune responses. The study examines emerging autoantibody synthesis after SCI with binding to conformational spinal cord epitopes and surface peptides located on the intact neuronal membrane.
METHODS
This is a prospective longitudinal cohort study conducted in acute care and inpatient rehabilitation centers in conjunction with a neuropathologic case-control study in archival tissue samples ranging from acute injury (baseline) to several months thereafter (follow-up). In the cohort study, serum autoantibody binding was examined in a blinded manner using tissue-based assays (TBAs) and dorsal root ganglia (DRG) neuronal cultures. Groups with traumatic motor complete SCI vs motor incomplete SCI vs isolated vertebral fracture without SCI (controls) were compared. In the neuropathologic study, B cell infiltration and antibody synthesis at the spinal lesion site were examined by comparing SCI with neuropathologically unaltered cord tissue. In addition, the CSF in an individual patient was explored.
RESULTS
Emerging autoantibody binding in both TBA and DRG assessments was restricted to an SCI patient subpopulation only (16%, 9/55 sera) while being absent in vertebral fracture controls (0%, 0/19 sera). Autoantibody binding to the spinal cord characteristically detected the substantia gelatinosa, a less-myelinated region of high synaptic density involved in sensory-motor integration and pain processing. Autoantibody binding was most frequent after motor complete SCI (grade American Spinal Injury Association impairment scale A/B, 22%, 8/37 sera) and was associated with neuropathic pain medication. In conjunction, the neuropathologic study demonstrated lesional spinal infiltration of B cells (CD20, CD79a) in 27% (6/22) of patients with SCI, the presence of plasma cells (CD138) in 9% (2/22). IgG and IgM antibody syntheses colocalized to areas of activated complement (C9neo) deposition. Longitudinal CSF analysis of an additional single patient demonstrated de novo (IgM) intrathecal antibody synthesis emerging with late reopening of the blood-spinal cord barrier.
DISCUSSION
This study provides immunologic, neurobiological, and neuropathologic proof-of-principle for an antibody-mediated autoimmunity response emerging approximately 3 weeks after SCI in a patient subpopulation with a high demand of neuropathic pain medication. Emerging autoimmunity directed against specific spinal cord and neuronal epitopes suggests the existence of paratraumatic CNS autoimmune syndromes.
Identifiants
pubmed: 37019668
pii: 10/3/e200099
doi: 10.1212/NXI.0000000000200099
pmc: PMC10075523
pii:
doi:
Substances chimiques
Autoantibodies
0
Epitopes
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NINDS NIH HHS
ID : R01 NS083942
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS099532
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS111582
Pays : United States
Organisme : Austrian Science Fund FWF
ID : I 4685
Pays : Austria
Organisme : NINDS NIH HHS
ID : R01 NS118200
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Clin Chem. 1991 Jul;37(7):1153-60
pubmed: 1855284
Nat Commun. 2016 May 18;7:11626
pubmed: 27188843
Brain. 2012 May;135(Pt 5):1622-38
pubmed: 22539258
J Spinal Cord Med. 2011 Nov;34(6):547-54
pubmed: 22330109
Front Neurol. 2018 Oct 10;9:841
pubmed: 30364136
Curr Opin Oncol. 2015 Nov;27(6):489-95
pubmed: 26335665
Nat Neurosci. 2018 Dec;21(12):1728-1741
pubmed: 30382196
Nat Rev Neurosci. 2019 Dec;20(12):728-745
pubmed: 31712781
BMC Neurol. 2013 Nov 09;13:168
pubmed: 24206943
Curr Opin Immunol. 1996 Dec;8(6):831-6
pubmed: 8994863
Ann Neurol. 2017 Feb;81(2):298-309
pubmed: 28120349
Methods Mol Biol. 2016;1304:211-29
pubmed: 25520281
J Neurosci. 2013 Aug 7;33(32):12970-81
pubmed: 23926252
Brain. 2021 Feb 12;144(1):144-161
pubmed: 33578421
Spinal Cord. 2007 Oct;45(10):678-86
pubmed: 17339890
Nat Rev Immunol. 2021 Dec;21(12):798-813
pubmed: 33976421
Nature. 2018 Sep;561(7724):547-550
pubmed: 30209395
Eur Spine J. 2012 May;21(5):964-70
pubmed: 22057439
Physiol Rev. 2017 Apr;97(2):839-887
pubmed: 28298428
J Neurotrauma. 2002 Jun;19(6):753-61
pubmed: 12165135
Brain. 2006 Dec;129(Pt 12):3249-69
pubmed: 17071951
J Immunol. 2012 Jun 1;188(11):5257-66
pubmed: 22523388
Trends Immunol. 2015 Nov;36(11):709-724
pubmed: 26494046
Neuroreport. 2016 Jan 20;27(2):90-3
pubmed: 26629661
Ann Neurol. 2007 Jan;61(1):25-36
pubmed: 17262855
Spine (Phila Pa 1976). 2010 Dec 15;35(26):E1604-9
pubmed: 21116216
J Autoimmun. 2007 Dec;29(4):246-9
pubmed: 17888625
Mult Scler. 1998 Jun;4(3):111-7
pubmed: 9762657
J Neuroinflammation. 2016 Sep 13;13(1):243
pubmed: 27618915
Nat Neurosci. 2017 Nov;20(11):1549-1559
pubmed: 28920935
Spinal Cord. 2009 Feb;47(2):122-7
pubmed: 18663374
J Clin Invest. 2009 Oct;119(10):2990-9
pubmed: 19770513
J Physiol Paris. 1995;89(3):129-36
pubmed: 7581302
J Immunol. 2021 Jul 1;207(1):90-100
pubmed: 34145056
Arch Neurol. 2012 Jun;69(6):714-7
pubmed: 22371852